Founded in 1996, the Foundation for Accreditation of Cellular Therapy (FACT) establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a non-profit corporation co-founded by the International Society for Cell and Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy (ASTCT), for the purposes of voluntary inspection and accreditation in the field of cellular therapy.
ISCT Board Representatives:
The Joint Accreditation Committee-ISCT & EBMT (JACIE) is a not-for-profit entity established in 1998 for the purposes of assessment and accreditation in the field of haematopoietic stem cell (HSC) transplantation. JACIE's primary aim is to promote high quality patient care and laboratory performance in haematopoietic stem cell collection, processing and transplantation centres through the development of global standards and an internationally recognised system of accreditation.
ISCT Representative, Uniform Donor History Questionnaire, CT Task Force: Phyllis Warkentin, MD
ISCT Representative, Circular of Information Cell Therapy Task Force (COI CT): J Wade Atkins, MS, MT(ASCP), SB
The partnership between ISCT and the Brazilian Association of Cell and Gene Therapy (ABTCel-Gen) aims to support the development of cell and gene therapies in Brazil and South & Central America through providing an increase in education, training, and networking opportunities and resources. Joint initiatives include organizing joint meetings and a membership referral program. ABTCel-Gen is an affiliate Society of Cytotherapy®, the Official Journal of ISCT.
ISCT and the Andalusian Network for the design and translation of Advanced Therapies (ANd&tAT) collaborate on initiatives that will support the training and development of the next generation of cell and gene therapy professionals in Europe. ISCT proudly provided 3 full tuition scholarships for 3 ISCT Europe Members to enroll in the 2021/2022 Master in Manufacturing of Advanced Therapy Medicinal Products (ATMPs) at the University of Granada/ ANd&tAT. ISCT and ANd&tAT have launched a series of on-line training modules covering cell and gene therapy manufacturing methods, quality assurance, product development pathways, GMP compliance, IMPD writing and biosafety
ISCT and ASTCT co-founded FACT in 1996 and collaborate to deliver the bi-ennial Cell Therapy Training Course.
ISCT signed a Memorandum of Understanding with the BAA in 2016 to foster collaborations in cell and gene therapy in the Australia & New Zealand Region. ISCT Cellular Therapy Representative:Janice Fogarty, MSc
ISCT and CARM collaborate to advance the development of safe and effective cell and gene therapies in Korea and the Asia region. CARM and ISCT have collaborated on projects since 2014 and signed a Memorandum of Understanding (MOU) in 2018.CARM Representative on the ISCT Commercialization Committee: Antonio Lee, PhD
ISCT and CBA collaborate on an Annual Cord Blood Connect workshop at the ISCT Annual Meeting, bringing together the global cord blood community.
ISCT and CellCAN collaborate on projects that advance the regenerative medicine ecosystem in Canada, including the Early Stage Professionals Training & Workforce Development Survey. CellCAN has also been the lead organization of the Canadian Pavilion, a showcase of Canadian cell and gene therapy companies in the Exhibit Hall at ISCT Annual Meetings since 2017.
ISCT and EATRIS signed a Memorandum of Understanding (MOU) in 2016 to foster collaboration and the advancement of cell and gene therapy translational research in Europe.
Since 1998 with the creation of the Joint Accreditation Committee of ISCT and EBMT (JACIE), EBMT and ISCT and EBMT have been in dialogue and project- based partnerships. ISCT and EBMT signed an MOU in 2019 to facilitate continued global collaborations and projects.
ISCT and FIRM have collaborated since 2015 and signed a Memorandum of Understanding (MOU) in 2017 to promote the development of the cell and gene therapy ecosystem in Japan. FIRM Representative on the ISCT Commercialization Committee:Yoshie Tsurumaki
ISCT has a representative on the ICCBBAA Cellular Therapy Coding and Labelling Advisory Group, which was established in 2004.
ISCT Representative, Cellular Therapy Coding and Labeling Group (CTLAG): Leigh Poston, BSc, MT(ASCP)
Drawing on ISEV’s expertise as a world leader in basic science of extracellular vesicles and ISCT’s depth of expertise in the translation of cell and gene therapy, ISCT and ISEV signed a memorandum of understanding in 2020 to facilitate collaborations in the areas of unproven cell & gene therapies as well as translation of promising EV research to the clinic.
ISCT is a Category A liaison to the International Standards Organization, providing key expertise in areas of new cell and gene therapy related standards.
ISCT Representative, Category A:
Sowmya Viswanathan, PhD
ISCT signed a memorandum of understanding with the Japanese Society for Regenerative Medicine in 2019 to advance regenerative medicine research towards a global audience. JSRM is the largest regenerative medicine society in the world (over 6,000 members) and ISCT provides an avenue for global translation.
ISCT has a long history of collaboration with KSBMT, bringing global translation expertise to the Korean BMT audience.
ISCT is a member of the National Academies of Sciences, Engineering, and Medicine’s Forum on Regenerative Medicine. The Forum convenes academia, industry, government, patient and provider organizations, regulatory bodies, foundations, societies, associations, and others to discuss challenges facing the application of, and the opportunities for, regenerative medicine to improve health through the development of effective new therapies.
ISCT and RMAF (formerly Strategic Center for Regenerative Medicine, SCRM) collaborate to advance the development of safe and effective cell and gene therapies in Korea and the Asia region. RMAF and ISCT have collaborated on projects since 2014 and signed a Memorandum of Understanding (MOU) in 2018.View Website
ISCT is a member of the Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-Based Drug Discovery (SCB), supporting the development of standards and best practices that support the cell and gene therapy industry.
ISCT Representative on the SCB Board of Directors:Kurt Gunter, MD
ISCT most recently collaborated with the Stem Cell Society of Singapore on a joint regional meeting in 2019, prior to the pandemic. This collaboration also provided a joint membership program. We look forward to collaborating with SCSS again in the future.
ISCT has been a voting member of USP since 2013.ISCT Representative: Joseph C. Laning, PhD
ISCT is a member Society of WBMT with an appointed representative who acts as the liaison between the two organizations. ISCT has also participated on the Alliance for Cellular Therapy Accreditation (AHCTA). ISCT Representative:Fermin Sanchez-Guijo, MD, PhD (Primary)Dominique Farge, MD, PhD (Alternate)
ISCT and WMDA collaborate to promote education around stem cell and cord blood banking and transplantation.
© 2021 ISCT. All rights reserved.
Site by eConverse Media